Oncology & Cancer

Zoledronic acid every 12 weeks noninferior in bone metastases

(HealthDay)—Use of zoledronic acid every 12 weeks does not result in increased risk of skeletal events compared with use every four weeks among patients with bone metastases due to breast cancer, prostate cancer, or multiple ...

Oncology & Cancer

Tasquinimod improves radiographic PFS in mCRPC

(HealthDay)—For chemotherapy-naive men with metastatic castration-resistant prostate cancer (mCRPC), tasquinimod is associated with improved radiographic progression-free survival (rPFS), according to a phase III study ...

Oncology & Cancer

Predicting advanced prostate cancer outcomes with NaF-PET/CT

A recent pilot study reported in the June issue of The Journal of Nuclear Medicine found that sodium fluoride (Na-F-18) positron emission tomography/computed tomography (NaF-PET/CT) accurately detects bone metastases in patients ...

Oncology & Cancer

ASCO: Cabozantinib improves progression-free survival in RCC

(HealthDay)—For patients with advanced renal cell carcinoma, cabozantinib is associated with improved progression-free survival (PFS), with consistent improvement across all patient subgroups, according to a study scheduled ...

page 2 from 7